VX 770 - Ivacaftor | Kalydeco

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 2503

CAS [873054-44-5]

MF C24H28N2O3
MW 392.49

Purity: 99%
Soluble in DMSO

VX 770

Description

Orally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels.

F. Van Goor et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30.

K.Y. Jih et al. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4404-9.

P.D. Eckford et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR.... J Biol Chem. 2012 Oct 26;287(44):36639-49.

Orally bioavailable CFTR potentiator

Chemical name

N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

Parent CAS No.

[873054-44-5]

产品资料